Search

Your search keyword '"Dearden, Claire"' showing total 813 results
Start Over Author "Dearden, Claire"
813 results on '"Dearden, Claire"'

151. Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report

Author

Montillo, Marco, primary, O'Brien, Susan, additional, Tedeschi, Alessandra, additional, Hillmen, Peter, additional, Dearden, Claire, additional, Gill, Devinder, additional, Brown, Jennifer R., additional, Barrientos, Jaqueline C., additional, Mulligan, Stephen, additional, Furman, Richard R., additional, Cymbalista, Florence, additional, Plascencia, Clara, additional, Chang, Stephen, additional, Hsu, Emily, additional, James, Danelle F., additional, and Byrd, John C., additional

Published
2014
Full Text
View/download PDF

152. BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

Author

Sascha, Dietrich, primary, Pircher, Andreas, additional, Andrulis, Mindaugas, additional, Ellert, Elena, additional, Peyrade, Frédéric, additional, Wendtner, Clemens-Martin, additional, Follows, George A, additional, Dyer, Martin JS, additional, Elter, Thomas, additional, Zeiser, Robert, additional, Gaehler, Anita, additional, Herrmann, Michael, additional, Herold, Michael, additional, Dearden, Claire, additional, Glimm, Hanno, additional, Hallek, Michael, additional, Ho, Anthony D, additional, Steurer, Michael, additional, and Zenz, Thorsten, additional

Published
2014
Full Text
View/download PDF

153. Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Author

Barrientos, Jacqueline C., primary, O'Brien, Susan, additional, Brown, Jennifer R., additional, Kay, Neil E., additional, Reddy, Nishitha M., additional, Coutre, Steven, additional, Tam, Constantine, additional, Mulligan, Stephen, additional, Jaeger, Ulrich, additional, Devereux, Steve, additional, Pocock, Christopher, additional, Robak, Tadeusz, additional, Schuster, Stephen J., additional, Schuh, Anna, additional, Gill, Devinder, additional, Bloor, Adrian, additional, Dearden, Claire, additional, Moreno, Carol, additional, Cull, Gavin, additional, Hamblin, Michael, additional, Jones, Jeffrey A., additional, Kierschniak, Tanja, additional, Eckert, Karl, additional, Suzuki, Samuel, additional, Hsu, Emily, additional, James, Danelle F., additional, Byrd, John C., additional, and Hillmen, Peter, additional

Published
2014
Full Text
View/download PDF

154. Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013

Author

Gleeson, Mary, primary, Hawkes, Eliza A, additional, Peckitt, Clare, additional, Wotherspoon, Andrew, additional, Attygalle, Ayoma, additional, Sharma, Bhupinder, additional, Du, Yong, additional, Ethell, Mark, additional, Potter, Michael, additional, Dearden, Claire, additional, Horwich, Alan, additional, Chau, Ian, additional, and Cunningham, David, additional

Published
2014
Full Text
View/download PDF

155. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013.

Author

Gleeson, Mary, Hawkes, Eliza A., Peckitt, Clare, Wotherspoon, Andrew, Attygalle, Ayoma, Sharma, Bhupinder, Du, Yong, Ethell, Mark, Potter, Mike, Dearden, Claire, Horwich, Alan, Chau, Ian, and Cunningham, David

Subjects
B cell lymphoma, RITUXIMAB, STEM cell transplantation, CANCER chemotherapy, REGRESSION analysis
Abstract

Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003–2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

156. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden Hospital experience.

Author

Sriskandarajah, Priya, Pawlyn, Charlotte, Mohammed, Kabir, Dearden, Claire E., Davies, Faith E., Morgan, Gareth J., Boyd, Kevin D., and Kaiser, Martin F.

Subjects
MULTIPLE myeloma, IMMUNOLOGICAL adjuvants, THALIDOMIDE, PROTEASOME inhibitors, DISEASE relapse
Abstract

The article discusses the efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients. It cites that Multiple myeloma (MM) is a molecularly and clinically heterogeneous disease making it difficult to control. The article also cites that despite the impact of novel agents such as immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, patients eventually exhaust all treatment options and reach the relapsed/refractory stage of disease

Published
2017
Full Text
View/download PDF

157. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma

Author

Coiffier, Bertrand, primary, Federico, Massimo, additional, Caballero, Dolores, additional, Dearden, Claire, additional, Morschhauser, Franck, additional, Jäger, Ulrich, additional, Trümper, Lorenz, additional, Zucca, Emanuele, additional, Gomes da Silva, Maria, additional, Pettengell, Ruth, additional, Weidmann, Eckhart, additional, d’Amore, Francesco, additional, Tilly, Hervé, additional, and Zinzani, Pier Luigi, additional

Published
2014
Full Text
View/download PDF

158. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma

Author

Barton, Sarah, primary, Hawkes, Eliza A., additional, Cunningham, David, additional, Peckitt, Clare, additional, Chua, Sue, additional, Wotherspoon, Andrew, additional, Attygalle, Ayoma, additional, Horwich, Alan, additional, Potter, Mike, additional, Ethell, Mark, additional, Dearden, Claire, additional, Gleeson, Mary, additional, and Chau, Ian, additional

Published
2014
Full Text
View/download PDF

160. Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Author

Hillmen, Peter, primary, Gribben, John G., additional, Follows, George A., additional, Milligan, Donald, additional, Sayala, Hazem A., additional, Moreton, Paul, additional, Oscier, David G., additional, Dearden, Claire E., additional, Kennedy, Daniel B., additional, Pettitt, Andrew R., additional, Nathwani, Amit, additional, Varghese, Abraham, additional, Cohen, Dena, additional, Rawstron, Andy, additional, Oertel, Stephan, additional, and Pocock, Christopher F.E., additional

Published
2014
Full Text
View/download PDF

162. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia

Author

Speedy, Helen E, primary, Di Bernardo, Maria Chiara, additional, Sava, Georgina P, additional, Dyer, Martin J S, additional, Holroyd, Amy, additional, Wang, Yufei, additional, Sunter, Nicola J, additional, Mansouri, Larry, additional, Juliusson, Gunnar, additional, Smedby, Karin E, additional, Roos, Göran, additional, Jayne, Sandrine, additional, Majid, Aneela, additional, Dearden, Claire, additional, Hall, Andrew G, additional, Mainou-Fowler, Tryfonia, additional, Jackson, Graham H, additional, Summerfield, Geoffrey, additional, Harris, Robert J, additional, Pettitt, Andrew R, additional, Allsup, David J, additional, Bailey, James R, additional, Pratt, Guy, additional, Pepper, Chris, additional, Fegan, Chris, additional, Rosenquist, Richard, additional, Catovsky, Daniel, additional, Allan, James M, additional, and Houlston, Richard S, additional

Published
2013
Full Text
View/download PDF

164. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk

Author

Crowther-Swanepoel, Dalemari, Broderick, Peter, Di Bernardo, Maria Chiara, Dobbins, Sara E., Torres, Maria, Mansouri, Mahmoud, Ruiz-Ponte, Clara, Enjuanes, Anna, Rosenquist, Richard, Carracedo, Angel, Jurlander, Jesper, Campo, Elias, Juliusson, Gunnar, Montserrat, Emilio, Smedby, Karin E., Dyer, Martin J. S., Matutes, Estella, Dearden, Claire, Sunter, Nicola J., Hall, Andrew G., Mainou-Fowler, Tryfonia, Jackson, Graham H., Summerfield, Geoffrey, Harris, Robert J., Pettitt, Andrew R., Allsup, David J., Bailey, James R., Pratt, Guy, Pepper, Chris, Fegan, Chris, Parker, Anton, Oscier, David, Allan, James M., Catovsky, Daniel, Houlston, Richard S., Crowther-Swanepoel, Dalemari, Broderick, Peter, Di Bernardo, Maria Chiara, Dobbins, Sara E., Torres, Maria, Mansouri, Mahmoud, Ruiz-Ponte, Clara, Enjuanes, Anna, Rosenquist, Richard, Carracedo, Angel, Jurlander, Jesper, Campo, Elias, Juliusson, Gunnar, Montserrat, Emilio, Smedby, Karin E., Dyer, Martin J. S., Matutes, Estella, Dearden, Claire, Sunter, Nicola J., Hall, Andrew G., Mainou-Fowler, Tryfonia, Jackson, Graham H., Summerfield, Geoffrey, Harris, Robert J., Pettitt, Andrew R., Allsup, David J., Bailey, James R., Pratt, Guy, Pepper, Chris, Fegan, Chris, Parker, Anton, Oscier, David, Allan, James M., Catovsky, Daniel, and Houlston, Richard S.

Abstract

To identify new risk variants for chronic lymphocytic leukemia (CLL), we conducted a genome-wide association study of 299,983 tagging SNPs, with validation in four additional series totaling 2,503 cases and 5,789 controls. We identified four new risk loci for CLL at 2q37.3 (rs757978, FARP2; odds ratio (OR) = 1.39; P = 2.11 x 10(-9)), 8q24.21 (rs2456449; OR = 1.26; P = 7.84 x 10(-10)), 15q21.3 (rs7169431; OR = 1.36; P = 4.74 x 10(-7)) and 16q24.1 (rs305061; OR = 1.22; P = 3.60 x 10(-7)). We also found evidence for risk loci at 15q25.2 (rs783540, CPEB1; OR = 1.18; P = 3.67 x 10(-6)) and 18q21.1 (rs1036935; OR = 1.22; P = 2.28 x 10(-6)). These data provide further evidence for genetic susceptibility to this B-cell hematological malignancy.

Published
2010
Full Text
View/download PDF

166. Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL).

Author

Barton, Sarah Rachel, primary, Hawkes, Eliza Anne, additional, Cunningham, David, additional, Peckitt, Clare, additional, Chua, Sue, additional, Wotherspoon, Andrew, additional, Attygalle, Ayoma, additional, Horwich, Alan, additional, Dearden, Claire E., additional, Potter, Mike, additional, and Chau, Ian, additional

Published
2013
Full Text
View/download PDF

167. A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.

Author

Byrd, John C., primary, Barrientos, Jacqueline Claudia, additional, Devereux, Stephen, additional, Brown, Jennifer R., additional, Kay, Neil E., additional, Reddy, Nishitha M., additional, O'Brien, Susan Mary, additional, Kipps, Thomas J., additional, Furman, Richard R., additional, Schuster, Stephen J., additional, Bloor, Adrian, additional, Gill, Devinder Singh, additional, Thornton, Patrick, additional, Dearden, Claire E., additional, Jäger, Ulrich, additional, Barker, Christine, additional, Lin, Jennifer, additional, Kunkel, Lori A., additional, James, Danelle Frances, additional, and Hillmen, Peter, additional

Published
2013
Full Text
View/download PDF

171. Long-term follow-up after purine analogue therapy in hairy cell leukaemia.

Author

Else, Monica, Dearden, Claire E., and Catovsky, Daniel

Abstract

Since 2006 when we last reviewed the literature concerning the use of purine analogues in hairy cell leukaemia (HCL), results from several new and updated series have been published. Here we examine these reports and consider their implications for patient management. The two purine analogues pentostatin and cladribine remain the first-line treatments of choice for all patients with HCL. Although they have not been compared in randomised trials, they appear to be equally effective. A complete response is important for the long-term outcome and we look at how best this can be achieved. Evidence is emerging which supports the use of either purine analogue plus an anti-CD20 monoclonal antibody after relapse, though questions remain concerning the scheduling of the monoclonal antibody. Patients refractory to the purine analogues may require alternative agents. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

172. An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy.

Author

Sarid, Nadav, Ahmad, Humayun N, Wotherspoon, Andrew, Dearden, Claire E, Else, Monica, and Catovsky, Daniel

Subjects
LEUKEMIA diagnosis, LEUKEMIA genetics, HYPERSPLENISM, RITUXIMAB, DISEASE relapse, ELASTICITY, DIAGNOSIS, THERAPEUTICS
Abstract

We describe three cases of relapsed hairy cell leukaemia (HCL) treated with pentostatin plus rituximab. All three achieved bone marrow complete remission but had persistent splenomegaly and hypersplenism. Because of the clinical uncertainty of its significance, they were all splenectomized. The spleen histology showed no evidence of HCL, but a five-fold thickening of the splenic capsule and areas of fibrosis in the red pulp. This process may have contributed to the lack of elasticity and caused the persistent splenomegaly. We discuss the clinical implications for future patient management. The three patients remain in remission at 1 +, 5 + and 9 + years. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

173. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD

Author

Dignan, Fiona L., primary, Potter, Mike N., additional, Ethell, Mark E., additional, Taylor, Matthew, additional, Lewis, Lily, additional, Brennan, Joy, additional, McNamara, Louise, additional, Evans, Steve O., additional, Riley, Unell, additional, Davies, Faith E., additional, Dearden, Claire E., additional, Morgan, Gareth J., additional, and Shaw, Bronwen E., additional

Published
2012
Full Text
View/download PDF

175. Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration

Author

Lin, Ke, primary, Adamson, Janet, additional, Johnson, Gillian G., additional, Carter, Anthony, additional, Oates, Melanie, additional, Wade, Rachel, additional, Richards, Sue, additional, Gonzalez, David, additional, Matutes, Estella, additional, Dearden, Claire, additional, Oscier, David G., additional, Catovsky, Daniel, additional, and Pettitt, Andrew R., additional

Published
2012
Full Text
View/download PDF

177. Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

Author

Pettitt, Andrew R., primary, Jackson, Richard, additional, Carruthers, Stacey, additional, Dodd, James, additional, Dodd, Susanna, additional, Oates, Melanie, additional, Johnson, Gillian G., additional, Schuh, Anna, additional, Matutes, Estella, additional, Dearden, Claire E., additional, Catovsky, Daniel, additional, Radford, John A., additional, Bloor, Adrian, additional, Follows, George A., additional, Devereux, Stephen, additional, Kruger, Anton, additional, Blundell, Julie, additional, Agrawal, Samir, additional, Allsup, David, additional, Proctor, Stephen, additional, Heartin, Earnest, additional, Oscier, David, additional, Hamblin, Terry J., additional, Rawstron, Andrew, additional, and Hillmen, Peter, additional

Published
2012
Full Text
View/download PDF

178. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Author

Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Moreno, Carol, Pagel, John M., Burger, Jan A., Suzuki, Samuel, Sukbuntherng, Juthamas, Cole, George, James, Danelle F., and Byrd, John C.

Abstract

Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours. It is unknown if intermittent interruption of ibrutinib therapy contributes to altered clinical outcomes. We therefore evaluated the effect of ibrutinib dose adherence on patient outcomes in the phase 3 RESONATE trial. The overall mean dose intensity (DI) was 95% with median treatment duration of ∼9 months. Pharmacokinetic assessment of ibrutinib exposure at 420-mg dose suggested similar exposure regardless of patient weight or age. As assessed by independent review committee, patients with higher DI experienced longer median progression-free survival (PFS) compared with those with lower DI regardless of del17p and/or TP53status. Of 79 patients requiring a drug hold, treatment was restarted at the original dose in 73 (92%) patients. Mean duration of a missed-dose event was 18.7 days (range, 8-56). Patients missing ≥8 consecutive days of ibrutinib had a shorter median PFS vs those missing <8 days (10.9 months vs not reached). These results support sustained adherence to once-daily ibrutinib dosing at 420 mg as clinically feasible to achieve optimal outcomes in patients with previously treated CLL. The trial was registered at www.clinicaltrials.govas #NCT01578707.

Published
2017
Full Text
View/download PDF

179. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Author

Grever, Michael R., Abdel-Wahab, Omar, Andritsos, Leslie A., Banerji, Versha, Barrientos, Jacqueline, Blachly, James S., Call, Timothy G., Catovsky, Daniel, Dearden, Claire, Demeter, Judit, Else, Monica, Forconi, Francesco, Gozzetti, Alessandro, Ho, Anthony D., Johnston, James B., Jones, Jeffrey, Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Larratt, Loree, Lauria, Francesco, Lozanski, Gerard, Montserrat, Emili, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme R., Rai, Kanti R., Ravandi, Farhad, Robak, Tadeusz, Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine, Tiacci, Enrico, Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, and Falini, Brunangelo

Abstract

Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the first-line and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients.

Published
2017
Full Text
View/download PDF

181. High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Has a Significant but Transient Impact on Quality of Life: Lessons From the Chronic Lymphocytic Leukemia (CLL) ASCT Study by the CLL Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

de Wreede, Liesbeth C., primary, Watson, Maggie, additional, Milligan, Donald, additional, Michallet, Mauricette, additional, Dreger, Peter, additional, van Os, Marleen, additional, Dearden, Claire E., additional, Cordonnier, Catherine, additional, Leporrier, Michel, additional, Koza, Vladimir, additional, Homewood, Janis, additional, Corront, Bernadette, additional, Baerlocher, Gabriela M., additional, Herr, Wolfgang, additional, Niederwieser, Dietger, additional, Sutton, Laurent, additional, de Witte, Theo M., additional, and Schetelig, Johannes, additional

Published
2011
Full Text
View/download PDF

183. Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Author

Marin-Niebla, Ana, primary, Else, Monica, additional, De la Cruz, Fatima, additional, Batty, Paul, additional, Rios-Herranz, Eduardo, additional, Dearden, Claire E., additional, Espigado, Ildefonso, additional, Simón, Jose Antonio Pérez, additional, Catovsky, Daniel, additional, and Matutes, Estella, additional

Published
2011
Full Text
View/download PDF

184. 5.46 NCRN CLL207 Study of Alemtuzumab Consolidation in Chronic Lymphocytic Leukaemia: Response Assessment Follow-up and Pharmacokinetic studies (on Behalf of the NCRI CLL Trials Sub-Group)

Author

Varghese, Abraham M., primary, Cohen, Dena, additional, Pocock, Christopher F., additional, Rawstron, Andy, additional, Gregory, Walter M., additional, Smith, Alex, additional, Skinner, Emma, additional, Critchley, Anne, additional, Milligan, Donald, additional, Dearden, Claire E., additional, McCarthy, Helen, additional, Fegan, Chris, additional, Follows, George A., additional, and Hillmen, Peter, additional

Published
2011
Full Text
View/download PDF

185. Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

Author

Gonzalez, David, primary, Martinez, Pilar, additional, Wade, Rachel, additional, Hockley, Sarah, additional, Oscier, David, additional, Matutes, Estella, additional, Dearden, Claire E., additional, Richards, Sue M., additional, Catovsky, Daniel, additional, and Morgan, Gareth J., additional

Published
2011
Full Text
View/download PDF

188. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence

Author

Else, Monica, primary, Dearden, Claire E., additional, Matutes, Estella, additional, Forconi, Francesco, additional, Lauria, Francesco, additional, Ahmad, Humayun, additional, Kelly, Susan, additional, Liyanage, Anandika, additional, Ratnayake, Vijitha, additional, Shankari, Jagadeesan, additional, Whalley, Ioana, additional, and Catovsky, Daniel, additional

Published
2011
Full Text
View/download PDF

189. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation

Author

Michallet, Mauricette, primary, Dreger, Peter, additional, Sutton, Laurent, additional, Brand, Ronald, additional, Richards, Sue, additional, van Os, Marleen, additional, Sobh, Mohamad, additional, Choquet, Sylvain, additional, Corront, Bernadette, additional, Dearden, Claire, additional, Gratwohl, Alois, additional, Herr, Wolfgang, additional, Catovsky, Daniel, additional, Hallek, Michael, additional, de Witte, Theo, additional, Niederwieser, Dietger, additional, Leporrier, Michel, additional, and Milligan, Donald, additional

Published
2011
Full Text
View/download PDF

190. Adherence To The Ibrutinib 420 mg Dose Administered To Patients With Previously Treated CLL

Author

Burger, Jan A., Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Carol Moreno, Pagel, John, Suzuki, Samuel, Sukbuntherng, Juthamas, Cole, George, James, Danelle F., and Byrd, John C.

Published
2015
Full Text
View/download PDF

194. Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Author

Hillmen, Peter, primary, Gribben, John G., additional, Follows, George A., additional, Milligan, Donald, additional, Sayala, Hazem A., additional, Moreton, Paul, additional, Oscier, David G., additional, Dearden, Claire E., additional, Kennedy, Daniel B., additional, Pettitt, Andrew R., additional, Nathwani, Amit, additional, Cohen, Dena, additional, Rawstron, Andy, additional, and Pocock, Christopher F.E., additional

Published
2010
Full Text
View/download PDF

195. NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Author

Varghese, Abraham M, primary, Cohen, Dena, additional, Pocock, Christopher F.E., additional, Rawstron, Andy, additional, Gregory, Walter M, additional, Smith, Alex, additional, Skinner, Emma, additional, Critchley, Anne, additional, Milligan, Donald, additional, Dearden, Claire E., additional, McCarthy, Helen, additional, Fegan, Chris, additional, Follows, George A, additional, and Hillmen, Peter, additional

Published
2010
Full Text
View/download PDF

196. Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Author

Varghese, Abraham M, primary, Sayala, Hazem A., additional, Moreton, Paul, additional, Jones, Richard A, additional, Rawstron, Andy, additional, Sheila, J, additional, Evans, Paul, additional, Anthony, Carter, additional, Dearden, Claire E., additional, Matutes, Estella, additional, Pettitt, Andrew R., additional, Kennedy, Daniel B., additional, Barrans, Sharon, additional, Worrillow, Lisa, additional, and Hillmen, Peter, additional

Published
2010
Full Text
View/download PDF

197. p53 protein overexpression in bone marrow biopsies from chronic lymphocytic leukaemia is associated with TP53 deletion and resistance to fludarabine

Author

Martin, Paloma, primary, Attygalle, Ayoma D., additional, Swansbury, John, additional, Min, Toon, additional, Morilla, Alison, additional, Hockley, Sarah L., additional, Wotherspoon, Andrew, additional, Morgan, Gareth J., additional, Catovsky, Daniel, additional, Dearden, Claire E., additional, and Matutes, Estella, additional

Published
2010
Full Text
View/download PDF

198. Chronic Lymphocytic Leukemia: New Concepts for Future Therapy

Author

Wierda, William G., primary, Chiorazzi, Nicholas, additional, Dearden, Claire, additional, Brown, Jennifer R., additional, Montserrat, Emili, additional, Shpall, Elizabeth, additional, Stilgenbauer, Stephan, additional, Muneer, Sabeeha, additional, and Grever, Michael, additional

Published
2010
Full Text
View/download PDF

199. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

Author

Krishnan, Biju, primary, Else, Monica, additional, Tjonnfjord, Geir E., additional, Cazin, Bruno, additional, Carney, Dennis, additional, Carter, John, additional, Ketterer, Nicolas, additional, Catovsky, Daniel, additional, Ethell, Mark, additional, Matutes, Estella, additional, and Dearden, Claire E., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results